A Sneak Peek At Medpace Holdings, Inc. ($MEDP) 3Q20 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) is set to announce third quarter earning results on Monday 26th October 2020, after market close.

Analysts surveyed by Thomson Reuters are predicting, MEDP to report 3Q20 income of $ 1.07 per share.

For the full year, analysts anticipate top line of $ 903.50 million, while looking forward to income of $ 3.74 per share bottom line.

The Company Outlook

Full Year 2020 topline are forecasted in a range of$ 880.00 million ~ $ 920.00 million, where as bottomline are predicted in a range of $ 3.62 ~ $ 3.83 per share

Click Here For More Historical Outlooks Of Medpace Holdings, Inc.

Previous Quarter Performance

Medpace Holdings, Inc. announced income for the second quarter of $ 0.64 per share, from the revenue of $ 205.00 million. The quarterly earnings dropped 20.99 percent while revenues down 4.25 percent compared with the same quarter last year.
Wall street analysts are predicting, MEDP to report 2Q20 income of $ 0.41 per share from revenue of $ 180.53 million. The bottom line results beat street analysts by $ 0.23 or 56.10 percent, at the same time, top line results outshined analysts by $ 24.47 million or 13.55 percent.

Stock Performance

On Friday, shares of Medpace Holdings, Inc. has traded high as $ 117.43 and has cracked $ 113.77 on the downward trend, reaching $ 116.54 with volume of 220.70 thousand shares.

According to the previous trading day, closing price of $ 116.54, representing a 98.48 % increase from the 52 week low of $ 58.72 and a 19.34 % decrease over the 52 week high of $ 144.49.

The company has a market capital of $ 4.13 billion and is part of the Healthcare sector and Diagnostics & Research industry.

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.